Background: Insular carcinoma is a little-known thyroid cancer, characterized by the presence of well-defined nidi of small uniform cells with frequent areas of tumor necrosis and microfollicles with thyroglobulin. It was described by Carcangiu in 1984, but its prognosis is not yet clear.
Study Design: Six of 335 patients undergoing surgery for thyroid carcinoma had the insular type. We studied age, gender, treatment, histology (tumor size, coexistence of another tumor, extrathyroid spread, vascular invasion, multicentricity, and metastatic adenopathies), TNM, and followup (recurrences, mortality, and survival). These results were compared with those published in the literature.
Results: Insular carcinoma was more common in women (4 of 6), and mean patient age was 32 years. Three patients had metastatic adenopathies. Four patients presented with other thyroid tumors (2 papillary, 1 follicular, and 1 anaplastic) and 2 were simple. Two patients had vascular invasion, and another 2 were extrathyroid. Only 1 case was multicentric. Three recurrences were detected in 2 patients over 50 years old: 1 lymph node at 60 months, 1 pulmonary at 132 months, and the other a bone recurrence at 8 months. Two patients died at 12 and 140 months.
Conclusions: Insular carcinoma is a special type of thyroid cancer, and the prognosis is poorer than for the classic differentiated thyroid carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1072-7515(98)00233-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiation-induced aberrant structural covariance networks in patients with nasopharyngeal carcinoma: a source-based morphometry study.
Quant Imaging Med Surg
December 2024
Department of Radiology, Xiangya Hospital, Central South University, Changsha, China.
Background: Radiation-induced brain injury (RBI) is a common complication in patients with nasopharyngeal carcinoma (NPC) who have undergone radiotherapy (RT), which is characterized by significant cognitive and psychological impairments. Although radiation-induced regional structural abnormalities have been well-reported, the effects of RT on the whole brain structural covariance networks are mostly unknown. Here, we performed a source-based morphometry (SBM) study to solve this issue.
View Article and Find Full Text PDFComplex Management of Brain Metastases in Head and Neck Squamous Cell Carcinoma: A Case Report and Literature Review.
Cureus
November 2024
Department of Neurosurgery, Santa Maria delle Grazie Hospital, Azienda Sanitaria Locale Napoli 2 Nord, Pozzuoli, ITA.
Head and neck squamous cell carcinoma (HNSCC) can, in rare instances, metastasize to the CNS, which is often associated with a poor prognosis. We present the case of a 65-year-old male with a history of HNSCC who developed two enhancing brain lesions: one in the right parietal region and another in the right insular region. Initially, the patient was managed with CyberKnife radiosurgery targeting both lesions.
View Article and Find Full Text PDFPerioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.
J Immunother Cancer
October 2024
Departament of Medical Oncology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Comunidad de Madrid, Spain
Article Synopsis
- The study investigates the effectiveness of perioperative chemoimmunotherapy (ChIO) in non-small cell lung cancer (NSCLC), focusing on the role of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH).
- It involved 24 NSCLC patients, assessing their HLA status and integrating molecular data and clinical outcomes to understand how tumors with HLA class I defects respond to ChIO.
- Results showed that both HLA-deficient and proficient tumors had similar rates of complete pathological response and survival, with strong immune responses observed in HLA-deficient tumors after treatment.
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.
Lancet Oncol
November 2024
Servicio de Oncología Médica, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Article Synopsis
- - The NADIM trial was a phase 2 study in Spain that evaluated the effects of perioperative immunotherapy on long-term outcomes in patients with stage IIIA non-small-cell lung cancer (NSCLC), showing positive short-term results previously. - A total of 46 treatment-naive patients participated, receiving a combination of chemotherapy and nivolumab before surgery, followed by more nivolumab as adjuvant therapy, with the study measuring 5-year progression-free and overall survival rates. - Findings showed that after 5 years, 65% of patients were progression-free and 69% had overall survival, with disease progression seen in 24% of patients and 30% dying by the end of the follow-up period.
Management strategy of primary ovarian mucinous carcinoid tumor: A rare case report.
Medicine (Baltimore)
September 2024
Department of Obstetrics and Gynecology, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, Seoul, Korea.
Article Synopsis
- Primary ovarian carcinoid tumors are very rare, with only about 30 cases reported since they were first identified in 1939; they can be classified into various types, with mucinous forms being extremely uncommon.
- A 40-year-old woman experienced lower abdominal pain for three months, and imaging revealed a significant soft tissue mass, leading to laparoscopic surgery for diagnosis and treatment.
- After being diagnosed with a primary ovarian mucinous carcinoid tumor and receiving treatment, the patient's symptoms improved, highlighting the importance of surgical intervention and the need for further research on postoperative chemotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!